Tokyo's benchmark Nikkei 225 index has fallen more than 4% and other shares in Asia also sank after a retreat on Wall Street ...

The bidding war over biotechnology company Metsera (MTSR) has intensified, drawing fierce competition from pharmaceutical ...

Pfizer’s buyout bid for Metsera was deemed inferior to the latest bid from Novo Nordisk, putting the original agreement in ...

Pfizer CEO Albert Bourla called Novo Nordisk's bid for obesity drug developer Metsera an "illegal...end-run around antitrust laws." ...

Dow Jones Top Company Headlines at 7 PM ET: AMD Reports Sharply Higher Profits, Sales | IBM ... The chip maker reported steep gains in both profit and sales for the third quarter as it moved deeper ...

Pfizer Inc. upped its original $7.3 billion September offer to buy Metsera Inc., but the obesity specialist maintained that a now-improved unsolicited bid by semaglutide developer Novo Nordisk A/S is ...

Wall Street fell as tech giants slide; S&P 500 down 1.2%, Nasdaq drops 2%, Palantir and Nvidia lead losses, Metsera rises.

The revised bids are the latest unusual twist in the fight between big drugmakers over drug developer Metsera.

Stocks fell on Wall Street, pulled down by losses in the same big tech companies that have been the main drivers of the market’s rally so far this year.

The Danish company’s latest offer is more than 30% about what Pfizer initially agreed to pay, not counting potential ...

The battle for control of a promising obesity drug maker has intensified, with one pharmaceutical giant upping its bid to $10 ...

Novo Nordisk is raising the stakes in its push to outbid rival Pfizer for the development-stage drugmaker Metsera.